low-dose IL-2

DRUG3 trials

Sponsors

University of Virginia, Assistance Publique - Hôpitaux de Paris, HeJing

Conditions

Behcet's DiseaseMelanomaRecurrent Miscarriage

Phase 1

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

CompletedNCT03970954

Assistance Publique - Hôpitaux de ParisRecurrent Miscarriage

Start: 2021-01-05End: 2024-03-20Updated: 2025-09-12

Phase 2

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

CompletedNCT00928902

University of VirginiaMelanoma

Start: 1999-11-30End: 2005-03-31Updated: 2010-10-21

Low-dose IL-2 Treatment on Behcet's Disease

CompletedNCT04065672

HeJingBehcet's Disease

Start: 2021-10-12End: 2023-07-28Updated: 2024-04-03

Related Papers

Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial.

2026-01-07